论文部分内容阅读
心房颤动是临床常见的心律失常。最近几年,房颤因其较高的发病率和死亡率,越来越多地受到人们的重视。目前,抗心律失常药物在转复及维持房颤患者窦性心律方面显得有些力不从心。虽然新的治疗手段如肺静脉消融等已经有所进展,但是对于很多心房颤动患者,药物治疗仍然很重要。这些非药物治疗方法由于其适应证较窄、并发症较高或医疗费用较昂贵等原因只能使部分患者受益;抗心律失常药物(antiarrhythmic drug,AAD)治疗仍有着不可替代的作用。心房颤动的药物治疗包括:(1)恢复和维持窦性心律,常用Ⅰ类和Ⅲ类抗心律失常药;(2)允许心房颤动存在,通过减慢房室结传导控制心室率,常用Ⅱ类、Ⅳ类和洋地黄类药物。
Atrial fibrillation is a common clinical arrhythmia. In recent years, due to its high morbidity and mortality, atrial fibrillation has drawn more and more attention. At present, antiarrhythmic drugs appear to be somewhat inadequate in the recovery and maintenance of sinus rhythm in patients with atrial fibrillation. Although new treatments such as pulmonary vein ablation have been developed, medical treatment remains important for many patients with atrial fibrillation. These nonpharmacological treatments can only benefit some patients due to their narrower indications, higher complication rates or higher medical costs. Antiarrhythmic drugs (AAD) still play an irreplaceable role. Pharmacological treatment of atrial fibrillation include: (1) the recovery and maintenance of sinus rhythm, commonly used class Ⅰ and Ⅲ antiarrhythmic drugs; (2) to allow the presence of atrial fibrillation, by slowing the conduction of atrioventricular node control ventricular rate, commonly used Ⅱ , Class IV and digitalis drugs.